Perioperative systemic treatments in renal cell carcinoma

被引：3
作者：
Goswamy, Rohit [1 ,2 ]
Kalemoglu, Ecem [3 ]
Master, Viraj [2 ,4 ]
Bilen, Mehmet Asim [1 ,2 ]
机构：
[1] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[2] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Dept Biochem, Atlanta, GA USA
[4] Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA
来源：
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词：
renal cell carcinoma; neoadjuvant; adjuvant; kidney cancer; review; cancer; RCC (Renal Cell Carcinoma); outcomes; NIVOLUMAB PLUS CABOZANTINIB; HIGH-RISK; INTERFERON-ALPHA; PHASE-III; FOLLOW-UP; NEOADJUVANT AXITINIB; SURGICAL-MANAGEMENT; ADJUVANT PAZOPANIB; SURVIVAL ANALYSIS; DOUBLE-BLIND;
D O I：
10.3389/fonc.2024.1362172
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this review, we aim to provide a comprehensive assessment of the evolving landscape of the perioperative management in renal cell carcinoma (RCC), emphasizing its dynamic and intricate nature. We explore academic and clinical insights into the perioperative treatment paradigm of RCC. Up-to-date treatment options are discussed and the evolving role of neoadjuvant and adjuvant therapy in RCC is highlighted.
引用
收藏
页数：15
相关论文
共 88 条
  • [1] Albiges L, 2019, Ann Oncol, V30, pv359, DOI [10.1093/annonc/mdz249.007, DOI 10.1093/ANNONC/MDZ249.007]
  • [2] First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
    Albiges, Laurence
    Tannir, Nizar M.
    Burotto, Mauricio
    McDermott, David
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    George, Saby
    Kollmannsberger, Christian K.
    Gurney, Howard
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Castellano, Daniel
    Rini, Brian, I
    Choueiri, Toni K.
    Leung, David
    Saggi, Shruti Shally
    Lee, Chung-Wei
    McHenry, M. Brent
    Motzer, Robert J.
    [J]. EUROPEAN UROLOGY, 2022, 81 (03) : 266 - 271
  • [3] Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial
    Allaf, M.
    Kim, S. E.
    Harshman, L. C.
    McDermott, D. F.
    Master, V. A.
    Signoretti, S.
    Cole, S.
    Moon, H.
    Adra, N.
    Singer, E. A.
    Gills, J.
    Choueiri, T. K.
    Leibovich, B.
    Michaelson, M. D.
    Shuch, B.
    Lara, P. N.
    Heng, D. Y. C.
    Kapoor, A.
    Carducci, M. A.
    Haas, N. B.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1432 - S1433
  • [4] [Anonymous], 2024, Created with Biorender.com
  • [5] [Anonymous], 2024, Blockade of CTLA-4 or PD-1 Signaling in Tumor Immunotherapy
  • [6] Botrel TEA, 2020, J CLIN ONCOL, V38
  • [7] A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)
    Bex, Axel
    van Thienen, Johan V.
    Schrier, Mariette
    Graafland, Niels
    Kuusk, Teele
    Hendricksen, Kees
    Lagerveld, Brunolf
    Zondervan, Patricia
    van Moorselaar, Jeroen A.
    Blank, Christian
    Wilgenbos, Sofie
    Haanen, John
    [J]. FUTURE ONCOLOGY, 2019, 15 (19) : 2203 - 2209
  • [8] Bex A, 2019, JAMA ONCOL, V5, P164, DOI 10.1001/jamaoncol.2018.5543
  • [9] Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?
    Bigot, Pierre
    Fardoun, Tarek
    Bernhard, Jean Christophe
    Xylinas, Evanguelos
    Berger, Julien
    Roupret, Morgan
    Beauval, Jean-Baptiste
    Lagabrielle, Samuel
    Lebdai, Souhil
    Ammi, Myriam
    Baumert, Herve
    Escudier, Bernard
    Grenier, Nicolas
    Hetet, Jean-Francois
    Long, Jean-Alexandre
    Paparel, Philippe
    Rioux-Leclercq, Nathalie
    Soulie, Michel
    Azzouzi, Abdel-Rahmene
    Bensalah, Karim
    Patard, Jean-Jacques
    [J]. WORLD JOURNAL OF UROLOGY, 2014, 32 (01) : 109 - 114
  • [10] Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma.
    Bilen, Mehmet Asim
    Liu, Yuan
    Nazha, Bassel
    Brown, Jacqueline T.
    Osunkoya, Adeboya O.
    Williams, Sierra
    Session, Wilena
    Yantorni, Lauren Beth
    Russler, Greta
    Caulfield, Sarah
    Joshi, Shreyas S.
    Narayan, Vikram M.
    Filson, Christopher Paul
    Ogan, Kenneth
    Kucuk, Omer
    Carthon, Bradley Curtis
    Kissick, Haydn
    Master, Viraj A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
123456789